表观遗传学在获得性胆脂瘤发病机制中的作用:现状综述
OBJECTIVE: Cholesteatoma is a leading cause of hearing loss. There is evidence that cholesteatoma has a heritable component. Treatment includes multiple and aggressive surgeries. Research on non-surgical treatments is crucial to improve outcomes.…
要点
- 多数研究聚焦非编码RNA,少数涉及组蛋白修饰和RNA甲基化。
- 非编码RNA差异表达参与调控增殖与凋亡相关通路。
- miRNA-21等特定靶点及DNA甲基化、组蛋白修饰值得进一步研究。
核心结论
- 表观遗传改变可能通过多条生物学通路失调参与胆脂瘤发病。
主要发现
- 多数研究来自中国,仅少数纳入儿童受试者。
- 多数研究探讨非编码RNA作为表观遗传机制,1项研究组蛋白修饰,2项研究RNA甲基化。
- 胆脂瘤中多种非编码RNA存在差异表达,参与调控细胞因子及影响增殖与凋亡的分子。
临床怎么用
- 进一步鉴定miRNA-21等特定靶点及研究DNA甲基化和组蛋白修饰,有望开发胆脂瘤的生物标志物和靶向药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cholesteatoma is a leading cause of hearing loss. There is evidence that cholesteatoma has a heritable component. Treatment includes multiple and aggressive surgeries. Research on non-surgical treatments is crucial to improve outcomes. Epigenetic changes can be inherited or environmentally acquired. These changes are pharmaceutically reversible, and epigenetic research has led to the FDA approval of several agents used in cancer treatment. Our goal was to review the literature investigating epigenetics in cholesteatoma to understand its role in pathogenesis and identify targets for epigenetic agents. DATA SOURCES: PRIMSA 2020 statement was used as the framework. Cochrane, Embase, PubMed/Medline, Scopus, and Web of Science were searched for keywords related to epigenetics and middle ear cholesteatoma until October 2025. REVIEW METHODS: Two reviewers (PA and AC) screened the records. Disputed records were resolved by a senior author (TB). 769 records were retrieved, 26 deemed eligible for inclusion. RESULTS: Most studies were from China. Only a few included pediatric subjects. Most investigated non-coding RNAs as the epigenetic mechanism; although one study investigated histone modifications and two investigated RNA methylation. Overall, there was differential expression of several noncoding RNAs in cholesteatoma. These noncoding RNAs are involved in regulation of cytokines and molecules that affect proliferation and apoptosis. CONCLUSIONS: Epigenetic changes may contribute to the pathogenesis of cholesteatoma through dysregulation of several biological pathways. Further studies identifying specific targets such as miRNA-21 and those investigating DNA methylation and histone modifications have the potential to develop biomarkers and targeted pharmaceutical agents for the treatment of cholesteatoma.
引用
- Brar T, Catanzarite A, Arya P, et al. Role of Epigenetics in the Pathogenesis of Acquired Cholesteatoma-A State of the Art Review. Otolaryngol Head Neck Surg. 2026. PMID: 41603588. doi:10.1002/ohn.70135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。